Cargando…

Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification

BACKGROUND: This study aimed to characterize and differentiate the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy 2011 cut points through the modified Medical Research Council dyspnea scale (mMRC) and chronic obstructive pulmonary disease (COPD) assessment test (CAT). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, David B, Baker, Christine L, Zou, Kelly H, Higgins, Victoria S, Bailey, James T, Pike, James S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043424/
https://www.ncbi.nlm.nih.gov/pubmed/24920893
http://dx.doi.org/10.2147/COPD.S62104
_version_ 1782318902160654336
author Price, David B
Baker, Christine L
Zou, Kelly H
Higgins, Victoria S
Bailey, James T
Pike, James S
author_facet Price, David B
Baker, Christine L
Zou, Kelly H
Higgins, Victoria S
Bailey, James T
Pike, James S
author_sort Price, David B
collection PubMed
description BACKGROUND: This study aimed to characterize and differentiate the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy 2011 cut points through the modified Medical Research Council dyspnea scale (mMRC) and chronic obstructive pulmonary disease (COPD) assessment test (CAT). METHODS: Analysis of COPD patient data from the 2012 Adelphi Respiratory Disease Specific Program was conducted in Europe and US. Matched data from physicians and patients included CAT and mMRC scores. Receiver operating characteristic curves and kappa analysis determined a cut point for CAT and mMRC alignment and thus defined patient movement (“movers”) within GOLD groups A–D, depending on the tool used. Logistic regression analysis, with a number of physician- and patient-reported covariates, characterized those movers. RESULTS: Comparing GOLD-defined high-symptom patients using mMRC and CAT cut points (≥2 and ≥10, respectively), there were 890 (53.65%) movers; 887 of them (99.66%) moved from less symptomatic GOLD groups A and C (using mMRC) to more symptomatic groups B and D (using CAT). For receiver operating characteristic (area under the curve: 0.82, P<0.001) and kappa (maximized: 0.45) recommended CAT cut points of ≥24 and ≥26, movers reduced to 429 and 403 patients, respectively. Logistic regression analysis showed variables significantly associated with movers were related to impact on normal life, age, cough, and sleep (all P<0.05). Within movers, direction of movement was significantly associated with the same variables (all P<0.05). CONCLUSION: Use of current mMRC or CAT cut points leads to inconsistencies for COPD assessment classification. It is recommended that cut points are aligned and both tools administered simultaneously for optimal patient care and to allow for closer management of movers. Our research may suggest an opportunity to investigate a combined score approach to patient management based on the worst result of mMRC and CAT. The reduced number of remaining movers may then identify patients who have greater impact of disease and may require a more personalized treatment plan.
format Online
Article
Text
id pubmed-4043424
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40434242014-06-11 Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification Price, David B Baker, Christine L Zou, Kelly H Higgins, Victoria S Bailey, James T Pike, James S Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: This study aimed to characterize and differentiate the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy 2011 cut points through the modified Medical Research Council dyspnea scale (mMRC) and chronic obstructive pulmonary disease (COPD) assessment test (CAT). METHODS: Analysis of COPD patient data from the 2012 Adelphi Respiratory Disease Specific Program was conducted in Europe and US. Matched data from physicians and patients included CAT and mMRC scores. Receiver operating characteristic curves and kappa analysis determined a cut point for CAT and mMRC alignment and thus defined patient movement (“movers”) within GOLD groups A–D, depending on the tool used. Logistic regression analysis, with a number of physician- and patient-reported covariates, characterized those movers. RESULTS: Comparing GOLD-defined high-symptom patients using mMRC and CAT cut points (≥2 and ≥10, respectively), there were 890 (53.65%) movers; 887 of them (99.66%) moved from less symptomatic GOLD groups A and C (using mMRC) to more symptomatic groups B and D (using CAT). For receiver operating characteristic (area under the curve: 0.82, P<0.001) and kappa (maximized: 0.45) recommended CAT cut points of ≥24 and ≥26, movers reduced to 429 and 403 patients, respectively. Logistic regression analysis showed variables significantly associated with movers were related to impact on normal life, age, cough, and sleep (all P<0.05). Within movers, direction of movement was significantly associated with the same variables (all P<0.05). CONCLUSION: Use of current mMRC or CAT cut points leads to inconsistencies for COPD assessment classification. It is recommended that cut points are aligned and both tools administered simultaneously for optimal patient care and to allow for closer management of movers. Our research may suggest an opportunity to investigate a combined score approach to patient management based on the worst result of mMRC and CAT. The reduced number of remaining movers may then identify patients who have greater impact of disease and may require a more personalized treatment plan. Dove Medical Press 2014-05-28 /pmc/articles/PMC4043424/ /pubmed/24920893 http://dx.doi.org/10.2147/COPD.S62104 Text en © 2014 Price et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Price, David B
Baker, Christine L
Zou, Kelly H
Higgins, Victoria S
Bailey, James T
Pike, James S
Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification
title Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification
title_full Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification
title_fullStr Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification
title_full_unstemmed Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification
title_short Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification
title_sort real-world characterization and differentiation of the global initiative for chronic obstructive lung disease strategy classification
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043424/
https://www.ncbi.nlm.nih.gov/pubmed/24920893
http://dx.doi.org/10.2147/COPD.S62104
work_keys_str_mv AT pricedavidb realworldcharacterizationanddifferentiationoftheglobalinitiativeforchronicobstructivelungdiseasestrategyclassification
AT bakerchristinel realworldcharacterizationanddifferentiationoftheglobalinitiativeforchronicobstructivelungdiseasestrategyclassification
AT zoukellyh realworldcharacterizationanddifferentiationoftheglobalinitiativeforchronicobstructivelungdiseasestrategyclassification
AT higginsvictorias realworldcharacterizationanddifferentiationoftheglobalinitiativeforchronicobstructivelungdiseasestrategyclassification
AT baileyjamest realworldcharacterizationanddifferentiationoftheglobalinitiativeforchronicobstructivelungdiseasestrategyclassification
AT pikejamess realworldcharacterizationanddifferentiationoftheglobalinitiativeforchronicobstructivelungdiseasestrategyclassification